FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044763009> ?p ?o ?g. }

• W3044763009 endingPage "490" @default.
• W3044763009 startingPage "481" @default.
• W3044763009 abstract "Abstract Background Accompanied with profound efficacy, atypical antipsychotics (AAPs) contribute to metabolic adverse effects with few effective strategies to attenuate. Serotonin 5-HT2C receptor (HTR2C) plays a critical role in hyperphagia and weight gain induced by AAPs, and expression of phosphatase tensin homolog (PTEN) in the hypothalamus also affects feeding behavior and weight change. Moreover, PTEN has a physical crosstalk between PTEN and a region in the third intracellular loop (3L4F) of the HTR2C. Tat-3L4F has the property to disrupt crosstalk between PTEN and HTR2C. This is the first study to our knowledge to investigate the effect of Tat-3L4F on olanzapine-induced metabolic abnormalities and PTEN/ phosphatidylinositol 3-kinase/protein kinase B expression in the hypothalamus in rats. Methods The effects of Tat-3L4F were investigated through measuring body weight, food intake, and blood glucose. In addition, PTEN/phosphatidylinositol 3-kinase/protein kinase B level in the hypothalamus was detected by immunofluorescence assay and western blot. Metabolites in the liver tissue were detected by liquid chromatography-mass spectrometry and analyzed by multivariate analyses and pairwise comparison. Results Our results showed that hyperphagia and weight gain were evident in the olanzapine alone–fed rats but was attenuated after Tat-3L4F treatment. In addition, oral glucose tolerance test indicated blood glucose at 120 minutes was higher in the olanzapine alone–treated group than in groups treated with vehicle and olanzapine + Tat-3L4F (10 μmol kg−1 per day). Furthermore, compared with olanzapine alone treatment, treatment with Tat-3L4F (10 μmol kg−1 per day) significantly inhibited PTEN expression in the hypothalamus. The olanzapine alone–treated group had the highest bile acid level, followed by the olanzapine with Tat-3L4F (1 μmol kg−1) group, olanzapine with Tat-3L4F (10 μmol kg−1) group, and vehicle group. Conclusions Our present results reveal that Tat-3L4F is a potential pharmacological strategy for suppressing hyperphagia and weight gain induced by olanzapine, which acts through disrupting crosstalk between HTR2C and PTEN as a result of PTEN downregulation in the hypothalamus." @default.
• W3044763009 created "2020-07-29" @default.
• W3044763009 creator A5012790879 @default.
• W3044763009 creator A5034855502 @default.
• W3044763009 creator A5037458498 @default.
• W3044763009 creator A5041107856 @default.
• W3044763009 creator A5074195896 @default.
• W3044763009 creator A5091068751 @default.
• W3044763009 date "2020-07-25" @default.
• W3044763009 modified "2023-10-16" @default.
• W3044763009 title "A Novel Synthetic Interfering Peptide Tat-3L4F Attenuates Olanzapine-Induced Weight Gain Through Disrupting Crosstalk Between Serotonin Receptor 2C and Protein Phosphatase and Tensin Homolog in Rats" @default.
• W3044763009 cites W1587053645 @default.
• W3044763009 cites W1642016580 @default.
• W3044763009 cites W1967117930 @default.
• W3044763009 cites W1973933734 @default.
• W3044763009 cites W1978062162 @default.
• W3044763009 cites W1978934025 @default.
• W3044763009 cites W1980594332 @default.
• W3044763009 cites W1986484493 @default.
• W3044763009 cites W1989847464 @default.
• W3044763009 cites W2015686099 @default.
• W3044763009 cites W2016403730 @default.
• W3044763009 cites W2017331239 @default.
• W3044763009 cites W2026204366 @default.
• W3044763009 cites W2029267570 @default.
• W3044763009 cites W2033431868 @default.
• W3044763009 cites W2038500073 @default.
• W3044763009 cites W2048236996 @default.
• W3044763009 cites W2061128828 @default.
• W3044763009 cites W2087633248 @default.
• W3044763009 cites W2092025665 @default.
• W3044763009 cites W2111248735 @default.
• W3044763009 cites W2113107587 @default.
• W3044763009 cites W2132980997 @default.
• W3044763009 cites W2150458484 @default.
• W3044763009 cites W2161376690 @default.
• W3044763009 cites W2236340720 @default.
• W3044763009 cites W2258638677 @default.
• W3044763009 cites W2529914139 @default.
• W3044763009 cites W2560644536 @default.
• W3044763009 cites W2576089858 @default.
• W3044763009 cites W2610020118 @default.
• W3044763009 cites W2743028812 @default.
• W3044763009 cites W2749942745 @default.
• W3044763009 cites W2890261997 @default.
• W3044763009 cites W2890415448 @default.
• W3044763009 cites W2895448784 @default.
• W3044763009 cites W2912533688 @default.
• W3044763009 cites W2955989795 @default.
• W3044763009 doi "https://doi.org/10.1093/ijnp/pyaa001" @default.
• W3044763009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7689208" @default.
• W3044763009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32710540" @default.
• W3044763009 hasPublicationYear "2020" @default.
• W3044763009 type Work @default.
• W3044763009 sameAs 3044763009 @default.
• W3044763009 citedByCount "6" @default.
• W3044763009 countsByYear W30447630092020 @default.
• W3044763009 countsByYear W30447630092021 @default.
• W3044763009 countsByYear W30447630092022 @default.
• W3044763009 countsByYear W30447630092023 @default.
• W3044763009 crossrefType "journal-article" @default.
• W3044763009 hasAuthorship W3044763009A5012790879 @default.
• W3044763009 hasAuthorship W3044763009A5034855502 @default.
• W3044763009 hasAuthorship W3044763009A5037458498 @default.
• W3044763009 hasAuthorship W3044763009A5041107856 @default.
• W3044763009 hasAuthorship W3044763009A5074195896 @default.
• W3044763009 hasAuthorship W3044763009A5091068751 @default.
• W3044763009 hasBestOaLocation W30447630091 @default.
• W3044763009 hasConcept C118552586 @default.
• W3044763009 hasConcept C11960822 @default.
• W3044763009 hasConcept C126322002 @default.
• W3044763009 hasConcept C134018914 @default.
• W3044763009 hasConcept C170493617 @default.
• W3044763009 hasConcept C178666793 @default.
• W3044763009 hasConcept C185592680 @default.
• W3044763009 hasConcept C2775864247 @default.
• W3044763009 hasConcept C2776412080 @default.
• W3044763009 hasConcept C2776619155 @default.
• W3044763009 hasConcept C2777609662 @default.
• W3044763009 hasConcept C2779549131 @default.
• W3044763009 hasConcept C53910766 @default.
• W3044763009 hasConcept C55493867 @default.
• W3044763009 hasConcept C62478195 @default.
• W3044763009 hasConcept C71924100 @default.
• W3044763009 hasConcept C86554907 @default.
• W3044763009 hasConcept C98274493 @default.
• W3044763009 hasConceptScore W3044763009C118552586 @default.
• W3044763009 hasConceptScore W3044763009C11960822 @default.
• W3044763009 hasConceptScore W3044763009C126322002 @default.
• W3044763009 hasConceptScore W3044763009C134018914 @default.
• W3044763009 hasConceptScore W3044763009C170493617 @default.
• W3044763009 hasConceptScore W3044763009C178666793 @default.
• W3044763009 hasConceptScore W3044763009C185592680 @default.
• W3044763009 hasConceptScore W3044763009C2775864247 @default.
• W3044763009 hasConceptScore W3044763009C2776412080 @default.
• W3044763009 hasConceptScore W3044763009C2776619155 @default.
• W3044763009 hasConceptScore W3044763009C2777609662 @default.
• W3044763009 hasConceptScore W3044763009C2779549131 @default.

• next